14.5 ML atoltivimab-ebgn 33.3 MG/ML / maftivimab-ebgn 33.3 MG/ML / odesivimab-ebgn 33.3 MG/ML Injection [Inmazeb]
- RxCUI
- 2571685
- RxNorm name
- 14.5 ML atoltivimab-ebgn 33.3 MG/ML / maftivimab-ebgn 33.3 MG/ML / odesivimab-ebgn 33.3 MG/ML Injection [Inmazeb]
- Display name
- 14.5 ML atoltivimab-ebgn 33.3 MG/ML / maftivimab-ebgn 33.3 MG/ML / odesivimab-ebgn 33.3 MG/ML Injection [Inmazeb]
- Full name
- 14.5 ML atoltivimab-ebgn 33.3 MG/ML / maftivimab-ebgn 33.3 MG/ML / odesivimab-ebgn 33.3 MG/ML Injection [Inmazeb]
- Term type
- SBD
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:46
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761169 | Inmazeb | atoltivimab, maftivimab, and odesivimab-ebgn | 351(a) | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Inmazeb | ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN | Regeneron Pharmaceuticals, Inc. | 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa | 2025-12-15 | Warnings, Adverse reactions | 2571685 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa | 14.5 ML atoltivimab-ebgn 33.3 MG/ML / maftivimab-ebgn 33.3 MG/ML / odesivimab-ebgn 33.3 MG/ML Injection [Inmazeb] | SBD | 12 | These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020 | 20251215 |
| 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa | Inmazeb 483.3 MG / 483.3 MG / 483.3 MG in 14.5 ML Injection | PSN | 12 | These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020 | 20251215 |
| 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa | Inmazeb 483.3 MG / 483.3 MG / 483.3 MG per 14.5 ML Injection | SY | 12 | These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020 | 20251215 |
| 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa | Inmazeb (atoltivimab-ebgn 33.33 MG/ML / maftivimab-ebgn 33.33 MG/ML / odesivimab-ebgn 33.33 MG/ML) per 14.5 ML Injection | SY | 12 | These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020 | 20251215 |
| 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa | Inmazeb (atoltivimab-ebgn 483.3 MG / maftivimab-ebgn 483.3 MG / odesivimab-ebgn 483.3 MG) per 14.5 ML Injection | SY | 12 | These highlights do not include all the information needed to use INMAZEB safely and effectively. See full prescribing information for INMAZEB. INMAZEB ® (atoltivimab, maftivimab, and odesivimab-ebgn) injection, for intravenous use Initial U.S. Approval: 2020 | 20251215 |